consequences highly improbable and unlikely Methods and analysis How will AD triggering by NDO be established prior to potential inclusion? The detailed trial protocol suggests that this will be established within the trial -unless the authors have an existing database of eligible patients where this is known then there may be a high proportion of screen failures. Have the authors conducted any exploratory work to give an indication of the likelihood of recruitment feasibility? In UDS -how will DO triggered AD be differentiated from that triggered by DESD in practice? This may well be a useful outcome for this exploratory study -there is a high risk of this, as written, being simply an underpowered study from which there will be under confidence in drawing valid conclusions Given the exploratory nature of the study -have the authors established feasibility and data quality for the proposed 14 day bladder and bowel diaries, which I note include fluid consumption and output -both additionally burdensome? What do the authors suggest are the limits of adherence to study drug in the trial? What will be done for those participants failing these criteria? A sample size calculation based upon the proposed primary outcome may well be impossible, given previous work in this area which has concentrated on the LUTD outcomes but an exploratory trial such as this may well be employed to establish an effect size to allow the conduct of a fully powered trial -the authors noting that single centre trials have been small is really not justifiable -and may be unethical in terms of resource and effort wasted. Theres also: Neurourol Urodyn. 2017 Feb;36(2):414-421 Its principal, rather than principle investigator Outcome measures How is decrease in severity of AD classified to allow a 50% decrease? There is likely to be little variability in MoCA at baseline -treatment with fesoterodine has no effect on MMSE scores, there are no data on MoCA -how will the authors exclude random variation by 1 point or so over time and how is "improvement" defined? Are the authors using 2 separate versions, given the interval between tests? See also: Spinal Cord. 2018 Jan;56(1): 22-27. doi: 10.1038/sc.2017.94 . Epub 2017 Aug 8. What data are there on improvement in bristol stool chart scores in any similar study to make this a feasible outcome? Are the authors proposing to collect data on changes to concomitant medications and coexisting medical conditions during the study? As I am sure the authors recognize, in cystometry, there is an inverse association between cystometric bladder capacity and pressure -perhaps the authors might assess the volume at first DO? At what point do the authors propose to assess detrusor pressure? How will investigators deal with the random variance in UDS variables? Will investigators (UDS reporters) be blinded to patient participation in the study as a means of mitigating potential bias? Analysis As far as it goes, this is fair. The authors might also consider whether a per protocol or ITT analysis is planned, what they will do about drop outs and missing data how they will assess recruitment, screening and adherence failures, the degree to which assessments are completed -all of these will be valuable measures to collect in this proposed exploratory study Discussion The authors cannot know if the short term amelioration of AD by these means will reduce chronic complications -this is conjectural and cannot be answered here. The study cannot therefore provide insight into "how and to what extent individuals with SCI can benefit secondary from treatment of NDO" in this context" Tables:  Sex, not Reviewer's report: Protocol for a phase II, open-label exploratory study investigating the efficacy of fesoterodine for treatment of adult patients with spinal cord injury with neurogenic detrusor overactivity for amelioration of autonomic dysreflexia. This is an interesting proposal which extends the usual trial of antimuscarinic agents in NDO from SCI beyond urological management. The extension to autonomic dysreflexia and cerebrovascular outcomes makes this a novel proposal.
Minor point, some of the English needs revision for ease of reading, the sentence construction is, in places, cumbersome. For example, in the introduction-AD is one devastating example of, rather than for, autonomic dysfunction and perhaps the consequences, such as myocardial infarction, stoke or even death can be devastating.
è We thank the reviewer for this helpful comment. We have adjusted the manuscript accordingly.
Could the authors perhaps give an estimate of the frequency / prevalence of AD being triggered by DO? This is most usually a consequence of detrusor-sphincter dyssynergia or bladder overdistension, but the reader would, I feel, benefit from an understanding of the extent of the problem leading to the research question -the authors have published on this -BMC Med. Fesoterodine has no published studies of activity in NDO, only in OAB, of which some of the exposed sample will have DO -in many studies those with NDO will have been excluded. The authors need to firm up their use of terminology in this area -they use NDO and OAB interchangeably, NDO is a cystometric diagnosis, OAB a clinical diagnosis. Might I suggest adherence to ICS standard terminology in this area?
è We thank the reviewer for this comment. We revised the entire manuscript accordingly.
The authors list a large list of potential benefits from the findings of their study -however, the proposal notes that this is a 12 week phase II exploratory study. The authors should ensure that each potential outcome is able to be gathered from the outcome of their proposed study in this protocol. The proposed trial is only of twelve weeks -this would make evaluation of long-term cardiovascular and cerebrovascular health of individuals with SCI and reduce the incidence of costs related to hospitalizations due to secondary consequences highly improbable and unlikely è We thank the reviewer for this comment. We revised our manuscript accordingly on In UDS -how will DO triggered AD be differentiated from that triggered by DESD in practice? This may well be a useful outcome for this exploratory study -there is a high risk of this, as written, being simply an underpowered study from which there will be under confidence in drawing valid conclusions , non-adherence will be considered when individuals fail to intake fesoterodine consecutively (>5 days) or intermittent (>50% of all days within one cycle). è Therefore, as stated on Page 9 of 48: "Study drug compliance will be monitored using a diary, which identifies missed doses. Participants will be asked to indicate the days where a dose is missed." We also added the following statement in table 1 (Page 18 of 48): "Diary of missed doses will be reviewed (i.e. medication adherence) and a decision for future participation will be made".
What will be done for those participants failing these criteria?
è We thank the reviewer for this comment. Any individual that fails adherence will be interviewed for the reason(s) of non-adherence. o Interview at end of cycle #1: Besides being interviewed, each participant will undergo thorough instructions (by members of the study team) prior to cycle #2. Depending on the judgement of the principal investigator, an individual will be allowed to continue to participate in the study. o Interview at end of cycle #2: If an individual will adhere during the cycle #2, the individual will be allowed to participate in cycle #3. If an individual continues to fail adherence, the principal investigator will withdraw the individual from the study. If an individual fails adherence only during the cycle #2, then the principal investigator can withdraw the individual from the study (depending on the extent of non-adherence). o During cycle #3 prior to the efficacy assessments (UDS #2 and 24-hr ABPM #2):
If an individual fails adherence, the principal investigator will withdraw the individual from the study.
A sample size calculation based upon the proposed primary outcome may well be impossible, given previous work in this area which has concentrated on the LUTD outcomes but an exploratory trial such as this may well be employed to establish an effect size to allow the conduct of a fully powered trial -the authors noting that single centre trials have been small is really not justifiable -and may be unethical in terms of resource and effort wasted. Its principal, rather than principle investigator è We thank the reviewer for this comment. We revised the manuscript accordingly.
Outcome measures
How is decrease in severity of AD classified to allow a 50% decrease? There is likely to be little variability in MoCA at baseline -treatment with fesoterodine has no effect on MMSE scores, there are no data on MoCA -how will the authors exclude random variation by 1 point or so over time and how is "improvement" defined? Are the authors using 2 separate versions, given the interval between tests? See also: Spinal Cord. 
Analysis
As far as it goes, this is fair. The authors might also consider whether a per protocol or ITT analysis is planned, what they will do about drop outs and missing data how they will assess recruitment, screening and adherence failures, the degree to which assessments are completed -all of these will be valuable measures to collect in this proposed exploratory study è We thank the reviewer for this comment and feel it is important to describe our statistical approach. In potential cases where individuals are withdrawn or chose not to continue the trial, we will not have follow up on-treatment assessments (such as UDS and 24h-ABPM). Therefore, traditional ITT is not possible for these variables. Consequently, we plan a treatment exposure analysis but wish to identify important characteristics of individuals that do not complete the treatment phase.
è We revised the manuscript on Page 12 of 48 to: "For this feasibility study, we plan to present a treatment exposure analysis (i.e. looking at the effectiveness of those who successfully completed the treatment phase). Alongside this, we will investigate whether there are any pertinent characteristics, i.e. concurrent medication use, participants' demographics and injury variables, which differ between participants that will complete the trial or not."
Discussion
The authors cannot know if the short term amelioration of AD by these means will reduce chronic complications -this is conjectural and cannot be answered here. The study cannot therefore provide insight into "how and to what extent individuals with SCI can benefit secondary from treatment of NDO" in this context" è We thank the reviewer for this comment. We agree and have revised the discussion (Page 12 of 48) to: "Treatment of NDO will reduce, at best prevent, peripheral afferent stimulation to the spinal cord (resulting from bladder contractions) and therefore decrease potential irritation of the spinal autonomic circuits that are responsible for triggering AD. If successful in the short-term, Fesoterodine could be a potential treatment option to consequently reduce chronic cardio-and cerebrovascular complications in this population in the long-term."
Tables:
Sex, not gender è We thank the reviewer for this comment. We revised the Page 5, line 1 -this is still spef the culative and does rather suggest that this study might be able to answer the question, which is patently not the case -this sentence could be rephrased along the lines of "there may be then, the potential to protect….. Thank you for your comment. We revised the sentence on page 5 of 50, lines 8 to 11: "It is unknown, whether antimuscarinic treatment for NDO, i.e. Fesoterodine, affects the severity and frequency of AD. There may then be, the potential to protect cerebrovascular health, maintain (or even improve) cognitive function and finally lower stroke-risk after SCI."
The sentences after line 36 are a repeat of previous content -the section would end better with the research question alone
Thank you for your comment. However, this part has already been revised in responds to the reviewer's initial comments. We do not feel that removing this part will be beneficial to the manuscript. We also have shown previously that NDO is an independent predictor for AD during UDS in the SCI population [PMID: 29650001] .
Methods and analysis
In addition, the repeatability of detecting AD between the two same session UDIs in SCI women was good (κ = 0.67, 95 % CI 0.4-0.94) [PMID: 26055644] and in a mixed sex SCI population was moderate (k = 0.53, 95% CI -0. In addition, we added the following statement on page 8 of 50, lines 32 to 35: "Non-adherence will be considered when individuals fail to intake fesoterodine consecutively (>5 days) or intermittent (>50% of all days within one cycle)."
What actions will be taken in the event of under or over compliance?
Thank you. As mentioned in our first responds letter, "Study drug compliance will be monitored using a diary, which identifies missed doses. Participants will beasked to indicate the days where a dose is missed". However, it will not be possible (in this phase II clinical trial using an outpatient setting) to control whether an individual deliberately performs under or over compliance, i. 
